A.V. Sultanbaev1–3
1State Autonomous Healthcare Institution Republican Clinical Oncology Dispensary of the Ministry of Healthcare of the Republic of Bashkortostan, Ufa
2Bashkir State Medical University of the Ministry of Health of the Russian Federation, Ufa
3Republican Medical Genetic Center of the Ministry of Health of the Republic of Bashkortostan, Ufa
Sultanbaev Alexander V. — PhD (Medicine), Head of the Department of Antitumor Drug Therapy
State Autonomous Healthcare Institution of the Republic of Bashkortostan Regional Oncological Clinical Hospital
1 Lenina Str., Ufa, 480008, Russian Federation, tel.: +7-905-002-22-95, e-mail: rkodrb@yandex.ru
ORCID ID: 0000-0003-0996-5995
Abstract. The effectiveness of antitumor immunity is determined by various mechanisms of tumor antigen recognition, while it is known that the level of mutational load and expression of PDL ligands is the effectiveness of the use of drugs to control immune response points. The diversity of the repertoire of antigen receptors is determined by V (D) J recombinations in maturing T and B cells, which also determines the likelihood of formation and stability of specific antitumor immunity. The aim of this work is to review the scientific literature data on the possibility of using immunotherapy in ovarian cancer.
Material and methods. This review presents data on the main mechanisms of antitumor immunity and various predictors in its formation.
Results. From the presented analysis of literary sources it follows that ovarian carcinogenesis is accompanied by suppression of the antitumor activity of the immune system, as a result of which immunodeficiency states are observed in patients with malignant neoplasms. Quantitative analysis of TREC and KREC in cancer patients allows to determine the presence of immunodeficiency, as well as to evaluate the effectiveness of the formation of antitumor immunity and the use of immune drugs.
Conclusions. The review reflects the mechanisms of the immune system response to ovarian carcinogenesis, the results of the use of various antitumor drugs and their effect on local immunity. The main stages of the interaction of tumor antigen with the patient’s immune system are considered. Markers of antitumor immunity are described.
Key words: ovarian cancer, excision rings of DNA recombination, TCR, BCR, TMB, PD1, PDL1.